Mitoquinone mesylate

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameMitoquinone mesylate
Drug Alias NameMitoQMitoQ10
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHypoxia-inducible factor 1 alpha inhibitors
TargetsHypoxia-inducible factor 1 alpha
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)SchizophreniaCognitive Dysfunction +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAntipodean
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterYale UniversityUniversity Of Lausanne +[5] 
Inactive CompaniesOregon Health And Science UniversityAntipodean Pharmaceuticals IncNational Institute On Aging (NIA)
Active IndicationsCoronavirus Disease 2019 (COVID-19)SchizophreniaCognitive Dysfunction +[8] 
Inactive IndicationsLower Urinary Tract SymptomsFatigueUrinary Bladder, Overactive +[7] 

Other Information

ATC CodeN/A
Related LinksDrugBank